Literature DB >> 19960277

Unusual case of a sigmoid mass.

Caris Grimes1, Olatunde Lalude.   

Abstract

BACKGROUND: Endometrial carcinoma is a relatively common condition which may occur with more than 6,400 new cases diagnosed each year in the UK (Cancer Research UK Statistics http://info.cancerresearchuk.org/cancerstats/types/uterus ). It may occur following hysterectomy especially if associated with prolonged hormone replacement therapy. CASE: We report the case of a 63-year-old lady who presented with a tumour in the sigmoid mesentery 13 years after hysterectomy and following 10 years of tamoxifen therapy for a breast carcinoma. This is the first time that endometrial cancer has been reported as a complication of tamoxifen therapy in the absence of a uterus.
CONCLUSION: We suggest that endometrial carcinoma remains a differential diagnosis of any pelvic or abdominal mass even after hysterectomy, and a history of intake of oestrogen agonists and antagonists needs to be obtained.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19960277     DOI: 10.1007/s12029-009-9103-x

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  4 in total

1.  Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1998-05-16       Impact factor: 79.321

2.  Malignancy arising in extraovarian endometriosis during estrogen stimulation.

Authors:  F Gücer; D Pieber; M G Arikan
Journal:  Eur J Gynaecol Oncol       Date:  1998       Impact factor: 0.196

3.  Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer.

Authors:  Raquel P Dibi; Claudio G Zettler; Suzana A Pessini; Alice V Ayub; Suzane B de Almeida; Gustavo P G da Silveira
Journal:  Menopause       Date:  2009 Mar-Apr       Impact factor: 2.953

4.  Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer : comparison of cohorts treated with and without tamoxifen.

Authors:  Mandana Saadat; Pauline T Truong; Hosam A Kader; Caroline H Speers; Eric Berthelet; Elissa McMurtrie; Ivo A Olivotto
Journal:  Cancer       Date:  2007-07-01       Impact factor: 6.860

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.